I have to write this special post on avandia as many of my patients at present are on it. Unfortunatelty people responsible for this controversy will not lay to rest the issue that has long been addressed. In short this is plain OLD issue that has been repackaged and made again into a media hype! The problem is the laymen – our patients who read the news and interpret the news as they are written.
Here is the response of the American Association of Clinical Endocrinologists: the Voice of Endocrinology on this particular issue. The same sentiments as I have. It is just unfortunate that this drug is involved in the midst of a controversy inside the FDA.
___________________________________________________________________________________________
AACE Patient Safety – Editorials | |
Commentary on February 19 New York Times article on Avandia
2010-02-22 15:41:32
By: Alan Garber, MD, PhD Editor, AACE Patient Safety Exchange
|
___________________________________________________________________________________________
So to my patients: no need to worry. Again this is an old issue repackaged by the New York Times made big in the headlines due to Senate inquiry.
Unless the US FDA will succumb to the pressures by the media and the senate…. there is no reason for this drug not to be available to our patients who need it!
Subsequent proscpective- meaning better made studies like the RECORD, ACCORD and the BARI2D that looked at patient safety on avandia have consistently shown that those taking avandia had in fact lesser risk for cardiovascular mortality than the comparator drugs including a recent publication in UK that compared avandia to the commonly used sulfonylurea and metformin.
A Diabetes Care metaanalysis in 2008 likewise showed that Sulfonylurea -metfomin combination in fact also increases risk of heart attack but this study was never caught by the media. Again since this is only a metaanalysis- exactly the same kind of study that started the Avandia contorversy…it is a hypothesis driven article and therefore cant be trusted but worth proving by making prospective randomized trials.
I hope this article will clear some issues hounding the patients on avandia. Remember…one reason why we need to control a patient’s blood sugar together with cholesterol and blood pressure is to reduce a patient’s risk for heart attack and stroke!
In medical field…. Analysis of data is of paramount importance. Dont believe what you read in the news!